METHOD FOR MEASURING TRACER UPTAKE IN CEREBRAL TISSUE

Abstract

A method for measuring tracer uptake in cerebral tissue of a patient by analyzing cerebral images acquired by positron emission tomography, the cerebral images including an early image and a late image, includes selecting a region of interest within the early and late images, determining a first domain D.sub.E defined by all voxels of the region of interest of the early image whose intensity is greater than a first given value, determining a second domain D.sub.L defined by all voxels of the region of interest of the late image whose intensity is greater than a second given value, calculating average intensities <I.sup.L>|.sub.DE and <I.sup.L>|.sub.DL in the first domain D.sub.E and second domain D.sub.L, respectively, of the late image, and calculating ratio of the average intensities TDr=<I.sup.L>|.sub.DE/<I.sup.L>.sub.DL.

Claims

1. A method for measuring tracer uptake into cerebral tissue of a patient by analyzing cerebral images acquired by positron emission tomography, said cerebral images comprising a static early image acquired from injection of a tracer into the patient, and a static late image acquired with a given time delay with respect to the static early image, said method comprising: selecting a region of interest within said static early and late images, determining a first domain D.sub.E defined by all voxels of the region of interest of the static early image whose intensity is greater than a first given value, determining a second domain D.sub.L defined by all voxels of the region of interest of the static late image whose intensity is greater than a second given value, calculating average intensities <I.sup.L>|.sub.DE and <I.sup.L>|.sub.DL in the first domain D.sub.E and in the second domain D.sub.L, respectively, of the static late image, and calculating a ratio of the average intensities TDr=<I.sup.L>|.sub.DE/<I.sup.L>|.sub.DL.

2. The method of claim 1, further comprising spatially normalizing said static early and late images.

3. The method of claim 1, wherein the static early image is acquired within about 10 minutes from the injection of the tracer.

4. The method of claim 1, wherein the static late image is acquired after at least about 30 minutes from the injection of the tracer.

5. The method of claim 1, wherein the region of interest includes brain parenchyma.

6. The method of claim 1, wherein said first given value is comprised between 75% and 95% percentile, and said second given value is comprised between 80% and 99% percentile.

Description

[0024] Additional features and advantages of the method according to the invention will become clearer with the following detailed description of one embodiment of the invention, given with reference to the attached drawings that are provided purely by way of non-limiting example, in which

[0025] FIG. 1 is a diagram showing a method for acquiring PET images;

[0026] FIG. 2 is a diagram showing a method for measuring the tracer uptake according to the invention;

[0027] FIG. 3 shows an early PET image, that is taken after the injection of the tracer. The areas surrounded by closed lines represent the domain having the greatest flow, D.sub.E,

[0028] FIG. 4 shows a late PET image, that is taken with a particular time delay after the injection of the tracer. The areas surrounded by darker closed lines represent the domain having the greatest flow, D.sub.E, while the areas surrounded by lighter closed lines represent the domain having the greatest uptake, D.sub.L;

[0029] FIG. 5 shows the uptake domain D.sub.L in two different subjects, an amyloid-negative and an amyloid-positive subject; and

[0030] FIG. 6 shows a sagittal, coronal and axial section of an early image sample (top) and late image sample (bottom), which are spatially standardized and aligned in the Montreal Neurological Institute (MNI) space.

[0031] As indicated above, the method according to the invention may be applied to cerebral PET scans acquired using non-receptor tracers in general (also called “flow tracers”).

[0032] In a preferred embodiment, fluorinated tracers are used (marked with 18F) that are selective for the protein amyloid.

[0033] The amyloid tracers are used for the differential diagnosis of Alzheimer's disease. The presence of abnormal deposits of amyloid protein agglomerates is in fact the more selective Alzheimer's marker, the diagnosis of which is independent of the symptomatic evidence (see the most recent criteria established by the NIA-AA National Institute on Aging-Alzheimer's Association; Clifford R. Jack et. al. Toward a biological definition of Alzheimer's disease, Alzheimer's & Dementia (2018)).

[0034] As of today, three fluorinated tracers are commercially available that are selective for the protein amyloid: 18F-florbetapir (commercial name AMIViD, trademark of the pharmaceutical company Eli-Lilly), 18F-florbetaben (NeuraCeq, by Piramal) and 18F-flutemetamol (Vizamyl, by GE Healthcare).

[0035] Further examples of tracers that may be used for the purposes of the present invention are tracers that are selective for the tau protein (for example 18F-flortaucipir).

[0036] FIG. 1 describes a PET acquisition method that makes it possible to acquire two successive images required for the measurement method according to the invention. First of all, the patient is positioned in the scanner (100) and the tracer is injected (110). An acquisition is therefore carried out within between 0 and 10 minutes after all of the tracer has been injected (early acquisition, step 120). The acquisition may also start 1-2 minutes after injection, depending on the individual protocol and on the injection method. After this, the patient is taken out of the scanner and held in a suitable adjacent waiting room (130). After approximately 30-70 minutes after the injection, for example (the exact time depends on the tracer), the patient is positioned back in the scanner (140) for a second acquisition (late acquisition, step 150) that lasts for approximately 20 minutes (this duration is also dependent on the tracer). After this, the two static images or scans taken at two different times after the injection will be referred to as “early” (also indicated by E) and “late” (also indicated by L).

[0037] The PET images acquired are selected by the medical personnel in accordance with quality standards that are known to an expert in the field. In particular, the images that show an absence of motion artifacts, correct field of view that includes the entire brain parenchyma, and a sufficient signal-to-noise ratio will be selected. Despite being customary and well understood by a nuclear medicine physician, these qualitative recommendations are in the process of being defined by the competent bodies for amyloid tracers (see, for example, Neurol Sci. 2015 June; 36(6):1075-81. doi: 10.1007/s10072-015-2079-3. Recommendations from the Italian Interdisciplinary Working Group (AIMN, AIP, SINDEM) for the utilization of amyloid imaging in clinical practice. Guerra U P, Nobili F M, Padovani A, Perani D, Pupi A, Sorbi S, Trabucchi M.).

[0038] With reference to FIG. 2, the two static cerebral PET images are acquired for an individual for example between 0 and 10 minutes and for example approximately 30 minutes, respectively, from when the non-receptor tracer was administered, as described above (step 200).

[0039] First and second images (210) therefore proceed to be spatially standardized. The early image is typically used as the “moving image” and the late image as the “fixed image.”

[0040] Therefore, a region of interest is selected (brain ROI) that includes the brain parenchyma and excludes the theca, the ventricles, the cerebellum and the brain stem (220).

[0041] A region or domain D.sub.E is therefore determined within the context of the first PET image (early image), the voxels of which have a greater intensity value than a first preset level, for example corresponding to the 85% percentile (230). Furthermore, a region or domain D.sub.L is determined within the context of the second PET image (late image), the voxels of which have a greater intensity value than a second preset level, for example corresponding to the 95% percentile.

[0042] The average intensities <I.sup.L>|.sub.DE and <I.sup.L>|.sub.DL are then calculated in the domain D.sub.E and in the domain D.sub.L, respectively, of the late image.

[0043] Lastly, the ratio of the average intensities is then calculated according to the equation TDr=<I.sup.L>|.sub.DE/<I.sup.L>|.sub.DL.

[0044] Spatial Standardization (Step 210)

[0045] The spatial standardization step consists in researching a 6-parameter transformation matrix (3 translation and 3 rotation parameters), optimization metrics (Mutual Information) and software for looking for the minimum (for example ANTs, among the numerous ones available) in order to superimpose the early and late scans such that the anatomical regions coincide. This step is necessary, since the patient has been repositioned in the scanner between one scan and the other. Since the images are of the same patient and have been acquired using the same scanner, it is sufficient to use a 6-parameter transformation.

[0046] The PET images may optionally be standardized on cerebral models that are processed using magnetic resonance acquisitions and are available in anonymized databases in order to render the presentation and reading of the scans consistent with the anatomical conventions used in medicine. The additional effect would be that of being able to benefit from regionalized information (and therefore originating from a portion of the brain) instead of the sole global value calculated over the entire parenchyma. For this purpose, the additional spatial standardization of the existing templates makes it possible to immediately use numerous segmentations (atlases) that are available for clinical research.

[0047] Selecting a Region of Interest (Brain ROI) (Step 220)

[0048] This selection is made by means of mapping a suitable pre-segmented mask on the individual patient by means of non-linear transformation.

[0049] The pre-segmented mask mentioned above consists of a trace outlined on a three-dimensional “sample” image (available for free) that contains all of the brain, and various structures of which may be included/excluded at will. In order to be able to adapt this mask to the patient in question, it is necessary to take advantage of a spatial standardization method having a similar concept to that described in the “spatial standardization” point, with the difference that the transformation matrix is far more complex. The method is known as a non-linear transformation method and consists in defining a deformation field that moves the “sample” image closer to that of the patient by means of a point-to-point deformation. Even though the transformation is complex, the ingredients and the software to be used are the same as those described in the “spatial standardization” point. Once the deformation field has been found, it is applied to the mask to obtain the equivalent thereof in the patient's space (brain ROI).

[0050] This step ensures that the information to be analyzed originates from the regions of clinical interest in the brain parenchyma and not from confounding structures (for example the skull or the neck).

[0051] Determination of D.sub.E and D.sub.L (Step 230)

[0052] The selection of a large ROI based on anatomical factors, which are specific to each individual, is followed by a study of the statistics of the counts—that is of the intensity of the signal recorded—within the brain ROI itself.

[0053] Therefore, the voxels belonging to the brain ROI are selected and a few elementary statistics (quantiles) are calculated. The process may be carried out in principle using any computing software, even if some (for example, MATLAB, R or Python) allow for the process with great ease.

[0054] Therefore, the intensity value corresponding to a certain percentile of the distribution of the counts inside the brain ROI is calculated (it is worth remembering that, in this step, the early and late scans are co-located in the same space and therefore the brain ROI is applicable to both).

[0055] As indicated above, the region D.sub.E is defined by all the voxels belonging to the brain ROI of the “early” scan, the intensity of which is greater than the value that corresponds to the 85% percentile, for example, calculated over the distribution of the intensities. More generally, the percentile value may be between 75% and 95%; however, preliminary studies suggest an optimum value of around 85%.

[0056] As indicated above, the region D.sub.L is defined by all the voxels belonging to the brain ROI of the “late” scan, the intensity of which is greater than the value that corresponds to the 95% percentile, for example, calculated over the distribution of the intensities. More generally, the percentile value may be between 80% and 99%; however, preliminary studies suggest an optimum value of around 95%.

[0057] Calculating the Ratio of the Average Intensities (Steps 230-240)

[0058] This ratio is the TDr of the subject, or rather the ratio between the intensities calculated using two domains, one of which is defined on the first scan. However, the average intensities are always calculated over the second scan (late). In fact, while the region D.sub.L is already defined on the late scan, the region D.sub.E is defined on the early scan but is applied to the late scan (by virtue of the spatial co-location thereof after the recording).

[0059] The acronym of the method appropriately highlights the time delay implicit when applying the region D.sub.E to the late scan. All of the intensities are therefore calculated from the second scan for the two regions, one of which (the D.sub.E) has been defined on the first scan.

[0060] The method according to the invention, also referred to in the following as the Time-Delayed ratio (TDr) method, is a semi-quantification technique based on the kinetics of the tracer.

[0061] The kinetic information is derived from two static images or scans, in particular from an “early” image and from a “late” image.

[0062] The early scan is an acquisition that begins just before the injection process, during the injection process or immediately after the injection process (for example after a few minutes, in particular after 1-2 minutes), and lasts for a few minutes, in particular for less than 10 minutes, for example for approximately 5 minutes. The late scan is a standard static scan used to evaluate the amyloid PET (for example carried out 50-70 minutes or 90-110 minutes after the injection process depending on the tracer).

[0063] In approximately the first 5 minutes, the signal is dominated by the tracer in the blood flow such that this scan may also be taken as a representation of the perfusion. The TDr method differs from the SUVr method in terms of the definition of the uptake and reference regions of interest. In its simplest form, the TDr ratio is defined as TDr=<I.sup.L>|.sub.DE/<I.sup.L>|.sub.DL, where <I.sup.L>|.sub.DE is the average intensity measured on the late scan and averaged over the domain or region D.sub.E, while <I.sup.L>|.sub.DL is the average intensity measured on the late scan and averaged over the domain or region D.sub.L. The domains are a group of regions of interest defined in the early image and in the late image as follows:

D.sub.E=v ∈ E|I.sub.v≥I.sub.0.sup.E   (1)

D.sub.L=v ∈ L|I.sub.v≥I.sub.0.sup.L   (2)

where v represents the voxels in the image and I.sub.v is the intensity in v. D.sub.E and D.sub.L are therefore each a group of voxels whose intensity is greater than a given value (see FIGS. 3 and 4, for example). Therefore, TDr is an intensity ratio similar to the SUVr but the regions of interest used in the calculation are not predefined or determined by the data. These regions are, instead, adapted to the patient and differ from patient to patient (see FIG. 5, for example) and from image to image, again in the same patient (in the case of a longitudinal study).

[0064] The TDr method takes inspiration from the absolute quantification approach. The tracer initially flows in the blood flow and therefore slowly migrates into the tissues. It is therefore possible to select tissues having a high flow (limiting the research to the cortical areas) from the early image. If β-amyloid is present in these tissues, the tracer will bind to said tissues and we have the advantage of knowing that it is appropriately distributed and in a relatively large amount (high uptake). In contrast, if β-amyloid is absent, the tracer will almost certainly be washed out since the tissue is well perfused (effective removal).

[0065] The numerator in the TDr ratio therefore describes the intensity that is obtained in the late scan averaged over the voxels having a high blood flow defined in the early scan. As a result, a high <I.sup.L>|.sub.DE value corresponds to a high uptake, and vice versa.

[0066] Now, given that the absolute value for this intensity may vary between individuals for a variety of reasons (injected activity, blood flow, physiological characteristics, etc.), this intensity must be standardized. The denominator in the TDr ratio describes the intensity that is obtained in the late image on the voxels having a high uptake (specific or non-specific) that are defined in the same late scan. Therefore, instead of using a fixed reference tissue (such as the cerebellum), the domain having the greatest uptake is used, otherwise known as the hot spot, which may be identified in the gray matter or in the adjacent white matter.

[0067] This standardization to some extent frees the TDr from the constraints of accuracy of capturing the images and of defining a reference tissue. Another immediate benefit consists in the fact that D.sub.E and D.sub.L are defined on images that are acquired using the same scanner and are reconstructed using the same method. This means that the partial-volume effect (PVE)—although still present—is partially “compensated for” by the selection of the two domains in the same space. Due to this definition and to the selection of regions having a high flow, the measurement of the amyloid burden in these areas is more accurate since the contrast between the burden and the hot spot is greatest.

[0068] The domains D.sub.E and D.sub.L are determined by the features of the patient and reference regions or cortical atlases are not required. The domains typically consist of different separate regions of interest that provide local and global information. Therefore, similarly to the values obtained using the SUVr method, they may be combined or averaged in order to provide regional or consolidated information.

[0069] The TDr only requires basic images to be processed, consisting of a spatial recording with respect to the coordinates of a normative space, such as the reference of the Montreal Neurological Institute (MNI). The brain does not need to be segmented from the head. The only unique requirement is that the early scan (E) is recorded on the late scan (L) in the native space before every other spatial or intensity standardization. This makes it possible to minimize spatial resampling errors (FIG. 6).

[0070] Once the scans E and L have been aligned in the native space, the scan L guides the transformation to place the scans in the normative space (for example, MNI).

[0071] The implementation of the TDr method is mainly linear. It only requires an accurate recording of the early scan on the late scan such that the regions of interest of the domain D.sub.E may be correctly applied thereto; this is possible with a 6-parameter linear transformation, with the scan L as the fixed image. All the subsequent transformations (that is on the normative space) are applied to both the images E and L.

[0072] After appropriate registration of the images and once in the MNI space, a mask is applied to cut the scalp, brainstem, cerebellum and basal ganglia and to estimate the higher counts according to equations (1) and (2), in which, for example, I.sub.0.sup.E=0.85 percentile and I.sub.0.sup.L=0.99 percentile.

[0073] The use of specific regions of interest of the patient allows for more precise measurements, thereby allowing for greater reproducibility and therefore application to longitudinal studies, or rather the possibility of monitoring the response of the patient to anti-amyloid therapies, currently in phase III of the trial.

[0074] One variant of the analysis method proposed provides that the domain D.sub.L is used together with an anatomical atlas to identify subregions of interest. In this way, it is possible to obtain more complex information that may allow for the identification of specific accumulation patterns and therefore the typification of the patient to the advantage of the diagnostics and the response to the drugs.

[0075] The method proposed is already provided for this type of analysis, thus only requiring further spatial standardization as described in the second paragraph of the “spatial standardization” point.

[0076] The selection of the atlas for partitioning the cerebral subregions does not fall within the scope of the present method; in fact, there are several possibilities selected that are generally dictated by clinical opportunity reasons. However, the TDr method does not have any inherent limitations and was tested on a large variety of atlases that are reasonably adapted to the anatomy and have clinical significance. In fact, the only connection is that the intersection of the domain D.sub.L with any other region of the atlas is not zero.